Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

905 - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy


24 Nov 2018


Poster display - Cocktail


Radiation Oncology

Tumour Site

Breast Cancer


Umesh Velu


Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427


U. Velu1, P.S. Alurkar2

Author affiliations

  • 1 Radiation Oncology, Kasturba Medical College, 576104 - Manipal/IN
  • 2 Radiotherapy, Kasturba Medical College, 576104 - Manipal/IN


Abstract 905


RT in left-sided breast cancer can lead to an increased risk of coronary artery disease (CAD). The type of RT technique and volumes, use of systemic therapy and patient related factors determine the risk of CAD. However, these cardiac events do not manifest until 10 years after RT.


We contoured the coronary artery segments in women with left-sided breast cancer and analyzed the dose distribution parameters. The mean and maximum doses for the segments of coronary arteries were noted in 15 such patients who underwent adjuvant RT (42.5 Gy in 16 fractions). All the patients were treated by 3DCRT with standard two-field tangential RT technique, with or without a supraclavicular field.


Whole heart dose may not be the best predictor of all types of radiation induced heart disease. It was observed that the maximum and mean dose to the coronary arteries was 26.4 Gy and 8.8 Gy respectively. This predicts the average risk of coronary artery disease.


RT to the left chest wall can expose patients to an increased risk of CAD and there seems to be an association between the location of the RT beam and the location of the coronary events. Hence, radiation oncologists should utilize the tools and techniques available to reduce doses to cardiovascular structures.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Umesh Velu.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.